Psoriasis, a chronic inflammatory skin disease, is caused by infiltrating lymphocytes and associated cytokines, including tumor necrosis factor (TNF)α, interleukin (IL)6, and IL17. Effective treatments, including pathogenesisbased biological agents against psoriasis, are currently
under development. Although the role of reactive oxygen species (ROS) in the pathogenesis of psoriasis has been investigated, it remains to be fully elucidated; ROStargeted therapeutic strategies are also lacking at present. Therefore, the objective of the present study was to assess whether
H2, a ROS scavenger, has a therapeutic effect on psoriasisassociated inflammation by reducing hydroxyl radicals or peroxynitrite in the immunogenic psoriasis cascade. Three methods were used to administer H2: Drop infusion of saline containing 1 ppm H2 (H2saline), inhalation of 3% H2
gas, and drinking of water containing a high concentration (57ppm) of H2 (highH2 water). Treatment efficacy was estimated using the disease activity score 28 (DAS28) system, based on Creactive protein levels, and the psoriasis area and severity index (PASI) score, determined at baseline
and following each H2 treatment. Furthermore, levels of TNFα, IL6, and IL17 were analyzed. The DAS28 and PASI score of the three patients decreased during H2 treatment, regardless of the administration method. The psoriatic skin lesions almost disappeared at the end of the treatment.
IL6 levels decreased during H2 treatment in Case 1 and 2. IL17, whose concentration was high in Case 1, was reduced following H2 treatment, and TNFα also decreased in Case 1. In conclusion, H2 administration reduced inflammation associated with psoriasis in the three cases
examined and it may therefore be considered as a treatment strategy for psoriasisassociated skin lesions and arthritis.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
Document Type: Research Article
Department of Rheumatology and Orthopaedic Surgery, Haradoi Hospital, Higashiku, Fukuoka 8138588, Japan
Department of Dermatology, Haradoi Hospital, Higashiku, Fukuoka 8138588, Japan
MiZ Company, Fujisawa, Kanagawa 2510871, Japan
Department of Radiology, Haradoi Hospital, Higashiku, Fukuoka 8138588, Japan
Department of Internal Medicine, Haradoi Hospital, Higashiku, Fukuoka 8138588, Japan
Department of Orthopaedic Surgery, Kyushu University, HigashiKu, Fukuoka 8128582, Japan
Department of Cardiology, Haradoi Hospital, Higashiku, Fukuoka 8138588, Japan
Midorino Clinic, Higashiku, Fukuoka 8130025, Japan
Publication date: August 1, 2015
More about this publication?
Molecular Medicine Reports is a monthly, peer-reviewed journal available in print and online, that includes studies devoted to molecular medicine, underscoring aspects including pharmacology, pathology, genetics, neurosciences, infectious diseases, molecular cardiology and molecular surgery. In vitro and in vivo studies of experimental model systems pertaining to the mechanisms of a variety of diseases offer researchers the necessary tools and knowledge with which to aid the diagnosis and treatment of human diseases.
- Editorial Board
- Information for Authors
- Submit a Paper
- Subscribe to this Title
- Information for Advertisers
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites